Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by Pulse 2.0 discussing Cartherics’ innovative approach to using stem cells to develop new cancer therapies. Alan’s leadership and expertise underscore the company’s commitment to advancing cancer treatment and improving outcomes for patients. Read the article here: https://pulse2.com/cartherics-prof-alan-trounson-profile/
Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by Barbara Barkhausen, a German speaking, Asia-Pacific Correspondent for a variety of German, Austrian and Swiss newspapers. Barbara’s article, translated below, was published in a number of European newspapers, highlighting that the first baby born from a frozen embryo is now 40 years old – a result […]
Melbourne, Australia, 2 April 2024 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has entered a collaborative research agreement with TiCARos Co Ltd (“TiCARos”) to assess its proprietary CLIP-CAR technology in Cartherics’ induced pluripotent stem cell (iPSC)-derived natural killer […]
TISSUE FACTOR AS A NOVEL TARGET FOR CAR-NK CELLS
Melbourne, Australia, 20 March 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has executed an option agreement to evaluate intellectual property (IP) from The Ohio State University (Ohio […]
At Emergence 2024, Cartherics’ COO, Dr Ian Nisbet was interviewed by Wholesale Investor. In the interview, Ian discusses the company’s cutting-edge strategies in combating solid tumours through cell-based immunotherapy. From leveraging stem cells to navigating regulatory pathways and entering clinical trials, Cartherics is on a mission to redefine cancer treatment. This interview highlights the challenges, […]
Each year in Australia around 1815 women are diagnosed with ovarian cancer. In most cases the cancer will be diagnosed at an advanced stage, where it is very difficult to treat.
To help raise awareness for ovarian cancer, Cartherics hosted a Teal Ribbon Day afternoon tea. Our Teal Tea provided a great opportunity to bring people […]
Cartherics is pleased to announce that it will be attending Emergence 2024 – The Era of Abundance investment conference at the Hilton Sydney next week.
The company’s CEO, Prof. Alan Trounson AO, will be presenting at 11:14 am on Wednesday 28th February. His presentation will discuss:
Cartherics’ CEO, Prof. Alan Trounson AO was recently interviewed by Wholesale Investor to discuss the company’s latest developments and the future of solid tumour therapy. In the interview Alan, shares insights into Cartherics’ cutting-edge technology, including the use of gene-edited natural killer (NK) cells and the strategic approach to leveraging a robust IP portfolio for […]
There’s an urgent need for new treatment options for ovarian cancer patients who are often diagnosed at advanced stages when survival outcomes are worse. Cartherics’ lead cell therapy CTH-401 is a natural killer (NK) cell product designed to seek out and destroy the cells that cause ovarian cancer, with clinical trials planned for early next […]
Melbourne, Australia, 1 February 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has successfully completed a pre-investigational new drug (pre-IND) meeting with the US Food and Drug Administration (FDA) for a Phase I/II clinical trial of its […]
Cartherics’ mission is the development of novel, “off-the-shelf” (allogeneic) immune cell therapy products for the treatment of cancer.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
